Should you buy JNJ stock?
Johnson & Johnson is shaking off its stodgy image as it moves to develop a broad and underappreciated drug portfolio and spin off its consumer business. The stock, now priced around $173, trades for a reasonable 17 times projected 2022 earnings of $10.38 a ...
Is JNJ stock a buy or sell?
The Johnson & Johnson stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Is JNJ going to split?
Johnson & Johnson JNJ, +2.86% has long been viewed as a bellwether ... J&J announced in November that it is planning to split into two publicly traded companies: one focusing on consumer health, and the other housing its prescription-drug and medical ...
When will JNJ split again?
Johnson & Johnson, which was founded in 1886, said Friday that its split will occur in the next two years, if approved by the company’s board of directors. J&J's announcement comes just days after General Electric said that it plans to split into three separate companies. Shares of New Brunswick, New Jersey-based Johnson & Johnson climbed 2% ...
What will happen to JNJ stock when the company splits?
19. Rachel Warren: If you currently own shares of Johnson & Johnson like I do, when the company splits, you will own shares of both Johnson & Johnson, the new pharmaceutical/medical device entity, as well as the new yet-to-be-named consumer health business.
When did JNJ last split?
1996The last stock split announced by Johnson & Johnson was in 1996, when shares were split 2-for-1.
Is JNJ a good stock to buy now?
The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Is Johnson and Johnson overvalued?
We view the shares as slightly overvalued after their runup over the past six months, which we largely attribute to investors looking for a steady investment against a backdrop of inflation concerns, the war in Ukraine, and supply chain disruptions.
What is the forecast for JNJ stock?
Stock Price Forecast The 16 analysts offering 12-month price forecasts for Johnson & Johnson have a median target of 187.00, with a high estimate of 215.00 and a low estimate of 173.00. The median estimate represents a +7.66% increase from the last price of 173.70.
How many times does Johnson and Johnson pay dividends?
Dividend Summary There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 2.3.
Is JNJ a good stock to buy 2022?
Expectations For 2022 The firm expects to earn $10.15-$10.35 per share on $94.8 billion to $95.8 billion in sales. For the year, JNJ stock analysts call for adjusted profit of $10.28 per share on $96.44 billion in sales. Both measures would climb less than 10% year over year.
Does JNJ increase dividend in 2022?
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson today announced that its Board of Directors has declared a 6.6% increase in the quarterly dividend, from $1.06 per share to $1.13 per share.
What is the best stock for 2022?
Best S&P 500 stocks as of June 2022Company and ticker symbolPerformance year to date (percent)Occidental Petroleum (OXY)139.1%Marathon Oil (MRO)91.4%Coterra Energy (CTRA)80.7%Halliburton (HAL)77.1%6 more rows•May 31, 2022
Is Johnson and Johnson stock undervalued?
Johnson & Johnson's forward earnings multiple of 15.2 is still well below the multiple of the S&P 500 as a whole, making Johnson & Johnson stock look undervalued.
Is Johnson and Johnson a good company?
Johnson & Johnson is the world's largest health care company. It is also the highest paid drug company in the world. J&J remains at the top of the Big Pharma list of powerful corporations with more than $82 billion in annual revenue in 2020. Its top products include Tylenol, Stelara, Invega and various medical devices.
Is AMD a buy?
AMD stock has a decent IBD Relative Strength Rating of 75 out of 99. The Relative Strength Rating shows how a stock's price performance stacks up against all other stocks over the last 52 weeks. The best growth stocks typically have RS Ratings of at least 80.
How much revenue does J&J have in 2021?
J&J indicates that the consumer division is projected to generate sales of about $15 billion in 2021, while the faster-growing pharmaceuticals, medical devices, and medical technology unit is on track to deliver about $77 billion in revenue. J&J's consumer division has four brands that each produce over $1 billion in annual sales. It also owns 20 brands that each generate over $150 million in yearly revenues. 2 1
When will Johnson and Johnson split?
Johnson & Johnson (JNJ) will split into two public companies within the next 18 to 24 months.
Who is Mark Kolakowski?
Mark Kolakowski is a business consultant, freelance writer, and business school lecturer. He has been an expert in investing, and a market watcher for 40-plus years. He received his MBA in finance from The Wharton School of The University of Pennsylvania and is the author of the book Career Confidential: An Insider’s Guide to Business.
Is Johnson's baby powder carcinogenic?
A key risk for the consumer products company will be litigation claiming that Johnson's Baby Powder is carcinogenic. J&J has denied this claim vigorously. 2
Is Johnson and Johnson publicly traded?
Healthcare giant Johnson & Johnson ( JNJ) will divide itself into two publicly traded companies. One will inherit J&J's extensive portfolio of well-known consumer products, while the other will continue to develop, produce, and distribute pharmaceuticals, medical devices, and medical technology. Johnson & Johnson indicates that the transaction will take place sometime over the next 18 to 24 months and that the pharmaceutical, medical devices, and medical technology company will retain the Johnson & Johnson name. 1 2
Who is the CEO of J&J?
The incoming CEO of J&J, Joaquin Duato, will head the latter company when the split takes place. 1 2
What would happen if Johnson and Johnson split?
The split would result in a new Johnson & Johnson as well as a still-unnamed consumer health company.
Who is the CEO of Johnson and Johnson?
However, we know that the new Johnson & Johnson will be led by CEO Joaquin Duato.
Does William White have any positions in the securities mentioned in this article?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The company recently announced a major change to its business structure
When Johnson & Johnson ( JNJ 4.97% ) announced that it would be splitting its pharmaceutical and medical device businesses from its consumer health segment last month, investors were stunned. But, could this actually be a genius move on management's part? Fool contributor Rachel Warren explains, in this segment of Backstage Pass, recorded on Nov.
NYSE: JNJ
Rachel Warren: If you currently own shares of Johnson & Johnson like I do, when the company splits, you will own shares of both Johnson & Johnson, the new pharmaceutical/medical device entity, as well as the new yet-to-be-named consumer health business.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
When is this happening?
J&J says the full separation should be completed within 18 months to two years.
What are the J&J brands?
Consumer health company: Following the separation, this company will comprise J&J’s consumer brands, such as Band-Aid, Tylenol, Aveeno, Neutrogena, Listerine, and many others. According to the announcement, this company will include four $1 billion “megabrands,” along with 20 others worth over $150 million. They include skin products, essential health products, oral health, baby care, feminine care, and wound care. On its own, this company is expected to deliver 2021 revenue of $15 billion. J&J has not announced a name for this new entity.
Who is the CEO of J&J?
Here’s what J&J CEO Alex Gorsky had to say in a statement: “Following a comprehensive review, the Board and management team believe that the planned separation of the Consumer Health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth, and—most importantly—improve healthcare outcomes for people around the world.”
How much money did J&J make in 2020?
Altogether in 2020, J&J made $83 billion in revenue, and analysts estimate $94 billion in 2021 sales.
Is Pfizer a minority shareholder in Glaxo?
GlaxoSmithKline Plc plans to spin off its consumer business, a joint venture in which Pfizer holds a minority stake. Novartis AG is unwinding its shareholding in Swiss rival Roche Holding AG and has announced a strategic review of the Sandoz generic unit. Novartis previously sold a stake in Glaxo’s consumer health business, which owns brands like Sensodyne toothpaste and Advil painkillers.
Who is Sam Fazeli?
Bloomberg Intelligence senior pharmaceutical analyst Sam Fazeli talks about Johnson and Johnson’s plan to split into two companies with Bloomberg’s John Tucker.
Johnson & Johnson's upcoming corporate split, explained
Following the General Electric three-way corporate spin-off announcement, Johnson & Johnson (NYSE:JNJ) is coming in hot with news of its own split.
Will both companies be publicly traded?
Johnson & Johnson plans to list both companies on the public market. The company's name will be reserved for the drug company while the consumer products operation is set to get a fresh name.
When will JNJ separate?
Johnson & Johnson plans to officially pursue its split now, with the project completed in as soon as 18–24 months. Over the next 1–2 years, investors will get a clearer picture of what's happening to the stock, how it will separate, and what the transition will entail for shareholders (especially those in the retail space).
Why separate companies could protect Johnson & Johnson
Johnson & Johnson reports that the split will help simplify its increasingly complex corporation and focus on its drug operation.
Johnson & Johnson's corporate split versus Purdue's lawsuit-filled subsidiary
Purdue Pharma is often considered the villain of the opioid epidemic, but Johnson & Johnson played a key role too.
How JNJ stock is responding to the news
Following the news about the upcoming Johnson & Johnson split, JNJ stock increased about 2.7 percent overnight. The shares have since cooled, but the movement proves that investors are interested in the corporate reconfiguration to come.
What happens after a stock split?
Once the split is complete, shareholders will receive dividend payments from both new stocks.
How much will consumer health be in 2021?
In 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.
How long does it take Johnson and Johnson to separate?
The company is targeting the completion of the planned separation in 18 to 24 months.
Is Johnson and Johnson a conglomerate?
Johnson & Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.
Will dividends be smaller for both new companies?
Shares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.
Does Johnson and Johnson pay dividends?
Johnson & Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.
Is the impending spinoff of a company attractive?
In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.
